Aurobindo Pharma’s Unit VI in Hyderabad receives Establishment Inspection Report

14 Feb 2013 Evaluate

Aurobindo Pharma’s Unit VI, Cephalosporin oral formulations facility based in Hyderabad, India has received the Establishment Inspection Report (EIR) for the same. The Unit was re-inspected by US Food & Drug Administration (USFDA) in September 2012. This facility was re-inspected by USFDA subsequent to an import alert imposed in February 2011.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. 

Aurobindo Pharma Share Price

1177.60 -39.85 (-3.27%)
08-Dec-2025 15:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1790.05
Dr. Reddys Lab 1272.70
Cipla 1498.90
Zydus Lifesciences 920.90
Lupin 2061.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×